Özet:

Objective: Testicular cancers (Tca) are most common in men aged 20-34. Despite the increase in its incidence, the mortality rate from Tca decreases. In our study, it was aimed to evaluate the general characteristics, the treatments and survival of the patients who were followed up and treated with the diagnosis of Tca. Materials and Methods: In this study, patients who were admitted to Okmeydanı Training and Research Hospital and Abant İzzet Baysal University, Medical Faculty, Medical Oncology Outpatient Clinic between January 2004 and December 2014 with the diagnosis of Tca, were evaluated retrospectively. Results: In 324 (96.7%) of 332 patients included in the study with the diagnosis of Tca, testicular germ cell tumor (TGCT) was present. Of the patients, 150 (46.3%) had seminoma and 174 (53.7%) had non-seminoma tumors. The median age of patients with TGCT was 32 (minimum 18-maximum 81) years. Non-seminoma group was diagnosed at a younger age (p<0.05). The most common histology in the non-seminoma group was mixed germ cell tumor which was found in 135 patients (77.6%). The stage in which the patients were most diagnosed was stage I (seminoma 73.3% and non-seminoma tumor 44.3%, p<0.001). Distant metastasis was present in 3.5% of patients with seminoma and 32.7% of patients with non-seminoma tumor (p<0.001). It was observed that 98% of the patients in the seminoma group and 85.6% of the patients in the non-seminoma group were in the good prognostic group (p<0.001). Radiotherapy, which was applied in 90 (81.8%) patients, was the most applied treatment in the group with stage I seminoma. In stage I non-seminomatous group, the most common treatment was cisplatin-based combination treatments, which was given to 58 (75.3%) patients. The median follow-up period of patients with stage I seminoma was 60 (minimum 3-maximum 134) months, and the median follow-up period of patients with non-seminoma tumor was 69 (minimum 8-maximum 178) months. Three hundred twelve (96.3%) patients with TGCT survived and 145 (96.7%) in the seminoma group and 167 (96%) patients in the non-seminoma group survived (p>0.05). Conclusion: The majority of our patients were diagnosed at an early stage and were in the good prognostic group. Most of our patients survived during our followup period.

Anahtar Kelimeler: